HS
TEVA icon

HighVista Strategies’s Teva Pharmaceuticals TEVA Stock Holding History

HighVista Strategies’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-101,300
Closed -$2.23M – 164
2024
Q4 		$2.23M Buy
101,300
+16,200
+19% +$295K 0.83% 35
2024
Q3 		$1.53M Sell
85,100
-51,400
-38% -$900K 0.53% 78
2024
Q2 		$2.22M Buy
+136,500
New +$2.1M 0.81% 37
2024
Q1 		– Sell
-124,700
Closed -$1.3M – 153
2023
Q4 		$1.3M Buy
124,700
+400
+0.3% +$3.73K 0.47% 73
2023
Q3 		$1.27M Buy
+124,300
New +$1.16M 0.59% 47
2016
Q4 		– Sell
-51,000
Closed -$2.35M – 211
2016
Q3 		$2.35M Buy
51,000
+5,000
+11% +$261K 0.44% 64
2016
Q2 		$2.31M Buy
+46,000
New +$2.45M 0.44% 59

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

HighVista Strategies's TEVA Position: Q1 2025 in Review

HighVista Strategies sold out of Teva Pharmaceuticals (TEVA) in Q1 2025, closing a stake of 101,300 shares — an estimated $2.23M sold.

HighVista Strategies first reported a position in TEVA in Q2 2016 and held it in 7 quarters. The position peaked at $2.35M in Q3 2016. 560 funds tracked by Wall St. Rank hold TEVA as of Q1 2025.

  • HighVista Strategies reported no remaining Teva Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • HighVista Strategies sold 101,300 Teva Pharmaceuticals shares in Q1 2025, an estimated $2.23M.
  • HighVista Strategies first reported a position in Teva Pharmaceuticals in Q2 2016 and held it in 7 quarters.
  • HighVista Strategies's Teva Pharmaceuticals position peaked at $2.35M in Q3 2016.
  • 560 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2025.

Based on HighVista Strategies's 13F filing for Q1 2025, filed 15 May 2025.